• For patients in remission while on maintenance medication, the study investigates whether medication discontinuation can be reached in 12 months following a first episode illness.
  

• Predictors of relapse, and costs and benefits of maintenance therapy in terms of functioning, quality of life, side effects, carer's burden, negative symptoms and cognitive symptoms.
  

Inclusion Criteria:

• Male or female patients, from 18 to 65 years of age at Visit 1
• Patients must achieve a level of understanding and expressive capacity sufficient to communicate adequately with the study coordinator and to participate in cognitive testing.
• Patients must agree to cooperate with all tests and examinations required by the protocol. They must be willing to comply fully with treatment
• Patient must understand the nature of the study and must sign an informed consent document.
• Patients must be Cantonese speaking Han Chinese
• Patients must be diagnosed, according to the SCID for DSM-IV, with schizophrenia, schizoaffective disorder or schizophreniform psychosis.
• Patients must have good response to anti-psychotic treatment by achieving a rating of 2 or below in Clinical Global Impression Scale (CGI) Severity of illness; a rating of 4 or below in Improvement scale, and a rating of 3 or below in (conceptual disorganization, unusual thought content), a rating of 2 or below in (delusion, hallucinatory behavior) and a rating of 4 or below in (Suspiciousness) of Positive and Negative Syndrome Scale (PANSS) for at least 8 weeks

Exclusion Criteria:

• Female patients who are either pregnant or lactating.
• Patients previously on clozapine should be excluded from the study
• Significant medical illnesses including seizures.
• DSM-IV substance (alcohol or other drugs) abuse or dependence within the past 3 months.
• Judged clinically to be at serious suicidal risk.
• Treatment with an injectable depot neuroleptic within less than one of the patient's dosing intervals between depot neuroleptic injections prior to study entry.